3 Promising Penny Stocks With Market Caps Up To $800M

Apr 23, 2025
3-promising-penny-stocks-with-market-caps-up-to-$800m

editorial-team@simplywallst.com (Simply Wall St)

4 min read

In This Article:

The U.S. stock market has recently experienced a surge, driven by optimism surrounding reduced tariffs on China and a rally in the technology sector. For investors seeking opportunities beyond established giants, penny stocks—typically smaller or newer companies—present intriguing possibilities for growth and diversification. While the term “penny stocks” may seem outdated, these investments continue to offer potential when supported by strong financials and fundamentals. In this article, we explore three promising penny stocks that stand out as potential hidden gems in today’s market landscape.

Name

Share Price

Market Cap

Financial Health Rating

Safe Bulkers (NYSE:SB)

$3.21

$337.6M

★★★★☆☆

Tuya (NYSE:TUYA)

$1.99

$1.12B

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$1.05

$15.82M

★★★★☆☆

Flexible Solutions International (NYSEAM:FSI)

$3.77

$47.3M

★★★★★★

TETRA Technologies (NYSE:TTI)

$2.43

$309.8M

★★★★☆☆

Imperial Petroleum (NasdaqCM:IMPP)

$2.59

$77.04M

★★★★★★

BAB (OTCPK:BABB)

$0.79

$5.74M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$198.32M

★★★★★★

Lifetime Brands (NasdaqGS:LCUT)

$3.82

$84M

★★★★★☆

New Horizon Aircraft (NasdaqCM:HOVR)

$0.4827

$15.22M

★★★★★★

Click here to see the full list of 777 stocks from our US Penny Stocks screener.

Let’s dive into some prime choices out of the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: AbCellera Biologics Inc. focuses on discovering and developing antibody-based medicines for unmet medical needs in the United States, with a market cap of approximately $730.07 million.

Operations: The company’s revenue primarily comes from the discovery and development of antibodies, generating $28.83 million.

Market Cap: $730.07M

AbCellera Biologics, with a market cap of approximately US$730.07 million, remains unprofitable as its net loss widened to US$162.86 million for 2024 despite generating US$28.83 million in revenue. The company recently filed a shelf registration for various securities totaling US$43.18 million, indicating potential capital-raising activities amid its ongoing financial challenges. While the management and board are experienced, with average tenures of 2.3 and 5.6 years respectively, earnings are forecasted to decline by an average of 10.5% annually over the next three years despite projected revenue growth of 18.68% per year.

NasdaqGS:ABCL Debt to Equity History and Analysis as at Apr 2025

NasdaqGS:ABCL Debt to Equity History and Analysis as at Apr 2025

Simply Wall St Financial Health Rating: ★★★★☆☆


Leave a comment